Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm PharmaceuticalsRYTM +1.03%57 Days Sales Outstanding is 47.77 as of Jun. 2026, which is 4% below its 10-year median of 49.71. GuruFocus rates RYTM with a GF Score™ of 57/100 and a GF Value™ of $120.05 (Fairly Valued). The stock has 3 warning signs investors should review. Among 835 Biotechnology companies, Rhythm Pharmaceuticals ranks better than 66.83% on this metric.
Rhythm Pharmaceuticals (NAS:RYTM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Rhythm Pharmaceuticals Days Sales Outstanding Related Terms
Rhythm Pharmaceuticals Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Rhythm Pharmaceuticals's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals Days Sales Outstanding Chart
RYTM vs MIRM, COGT, ERAS: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Rhythm Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Pharmaceuticals Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Rhythm Pharmaceuticals's Days Sales Outstanding falls into.
Rhythm Pharmaceuticals Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (RYTM) has a Days Sales Outstanding of 47.77 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Rhythm Pharmaceuticals and its competitors. This is near median its historical median of 49.71. Over the past decade, Rhythm Pharmaceuticals' Days Sales Outstanding has ranged from 42.89 to 118.62. According to the industry distribution chart, Rhythm Pharmaceuticals ranks #277 out of 835 companies in the Biotechnology industry, placing it in the top 33.2%.
Is Rhythm Pharmaceuticals' Days Sales Outstanding too high?
Rhythm Pharmaceuticals' current Days Sales Outstanding of 47.77 is near median its 10-year median of 49.71. Over the past 10 years, this metric has ranged from a low of 42.89 to a high of 118.62. The Biotechnology industry median Days Sales Outstanding is 68.94. Rhythm Pharmaceuticals' value of 47.77 is 30.7% below this industry median. Based on the distribution chart, Rhythm Pharmaceuticals ranks #277 out of 835 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rhythm Pharmaceuticals has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Days Sales Outstanding compare to MIRM and COGT?
According to the Biotechnology industry distribution chart, Rhythm Pharmaceuticals ranks #277 out of 835 companies for Days Sales Outstanding. This puts Rhythm Pharmaceuticals in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. Rhythm Pharmaceuticals' value of 47.77 is 30.7% below this benchmark. Historically, Rhythm Pharmaceuticals' own Days Sales Outstanding has ranged from 42.89 to 118.62 over the past decade. While the company's 10-year median is 49.71 vs. the industry median of 68.94, Rhythm Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Pharmaceuticals's current Days Sales Outstanding of 47.77 is 30.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Rhythm Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Pharmaceuticals's current Days Sales Outstanding is 47.77, which is near median its own 10-year median of 49.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals (RYTM) is currently considered Fairly Valued. The stock's GF Value™ is $120.05, compared to a current price of $109.94 — trading 8.4% below its estimated fair value. The current Days Sales Outstanding is 47.77, which is near median its 10-year median of 49.71 and 30.7% below the Biotechnology industry median of 68.94. Rhythm Pharmaceuticals' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Rhythm Pharmaceuticals (RYTM), the current Days Sales Outstanding is 47.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of $109.94 is trading 8.4% below its estimated GF Value™ of $120.05.
GuruFocus considers Rhythm Pharmaceuticals to be Fairly Valued.
Key valuation signals for RYTM:
Days Sales Outstanding: 47.77 (near median its 10-year median of 49.71)
GF Value™: $120.05 vs. price of $109.94 (8.4% below fair value)
Industry Position: 30.7% below the Biotechnology median (#277 of 835)
No single metric tells the full story. See the RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
57GF Score
Get the complete analysis for RYTM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYTM has been successfully added to your 
